'Double-Digit Growth' Performance Behind CEO, $1.7 Million Share Sale Disclosure

Edwards Lifesciences Corp (EW) reported on February 10 that fourth-quarter 2025 revenue reached $1.57 billion, up approximately 13% year-over-year, and full-year 2025 sales grew by about 11%, driven by strong performances in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) businesses. For 2026, the company forecasts constant-currency revenue growth of 8–10%, TMTT sales growth of 35–45%, and adjusted EPS of $2.90–3.05, citing multiple growth catalysts on the clinical, regulatory and market fronts.

On February 12, CEO Bernard J. Zovighian exercised stock options and sold roughly $1.7 million worth of shares in the open market, then on February 13 reported transferring a portion of his holdings as gifts. Despite these transactions, his direct and indirect stake remains substantial.

Following the earnings release, Edwards Lifesciences’ share price outperformed key peers, climbing over 2% on February 11 even amid debate over short-term earnings pressures from expanded investment and the company’s growth trajectory beyond 2026. (Source: investors.com)

Edwards Lifesciences has also announced that its CFO will present at the TD Cowen Healthcare Conference on March 2, continuing the company’s dialogue with investors. (Source: edwards.com)

A global medtech leader, Edwards Lifesciences supplies transcatheter heart valves for structural heart disease (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valves, with product rollouts focused primarily in the U.S. and Europe. (Source: edwards.com)

As aging populations and rising cardiovascular disease rates drive rapid adoption of transcatheter valve procedures, medical-device companies worldwide are intensifying their R&D efforts in TAVR and mitral/tricuspid therapy devices to capture leadership in the structural heart disease treatment market.